Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Are doctors prescribing antithrombin correctly? a new study investigates

NCT ID NCT07276074

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks back at how antithrombin, a blood-clotting protein, was prescribed to 160 intensive care patients at Strasbourg University Hospitals over two years. Researchers want to see if these prescriptions were appropriate and how the drug was used in real-world settings. The goal is to improve future prescribing practices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
antithrombin
What this could lead to
If successful, this study could help hospitals create guidelines for better use of antithrombin, potentially improving patient safety and treatment effectiveness.
What could go wrong
This is a retrospective review, not a treatment trial. It only looks at past records, so it cannot prove cause and effect or change current care directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

\- Adult subject (≥18 years old) having received antithrombin during the study period, in intensive care or operating room during the period from January 1, 2022 to December 31, 2023.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult subject (≥18 years old) * Female and male * Having received antithrombin during the study period, in intensive care or operating room during the period from January 1, 2022 to December 31, 2023. Exclusion Criteria: * Subject (and/or their legal representative, if applicable) having expressed their opposition to the reuse of their data for scientific research purposes * Minor subject

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antithrombinemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hereditary antithrombin deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antithrombinemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Service d'Anesthésie et Réanimation chirurgicale - CHU de Strasbourg - France

    RECRUITING

    Strasbourg, France